CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DigitalDrugDesign–Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced presentations at the following investor conferences during the months of September and early October:
-
H.C. Wainwright 21st Annual Global Investment Conference
Corporate update
Presented by: CEO David Giljohann
Monday, September 9, 2019 at 10:25am ET
Location: New York, NY
-
Ladenburg Thalmann 2019 Healthcare Conference
Corporate update
Presented by: CEO David Giljohann
Tuesday, September 24, 2019 at 1:30pm ET
Location: New York, NY
-
Chardan’s 3rd Annual Genetic Medicines Conference
Corporate update
Presented by: Dr. David Giljohann
Monday, October 7, 2019 at 2:00pm ET
Location: New York, NYThe Next Big Thing in Genetic Medicines
Panelist: Dr. David Giljohann
Tuesday, October 8, 2019 at 9:30am ET
Location: New York, NY
An audio webcast will be available on the Investors section of Exicure’s website: www.exicuretx.com. The webcast will be archived for approximately 30 days following the event.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA. www.exicuretx.com
Contacts
MacDougall
Karen Sharma
781-235-3060
ksharma@macbiocom.com